| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
(S)-Amisulpride targets dopamine D2 and D3 receptors, acting as a selective antagonist. It has higher affinity for D3 receptors than for D2 receptors. By blocking these dopamine receptors, (S)-Amisulpride reduces dopaminergic neurotransmission, which is thought to be overactive in schizophrenia. The compound's selectivity for D2/D3 receptors over other receptors contributes to its antipsychotic efficacy and its lower risk of certain side effects, such as extrapyramidal symptoms, compared to typical antipsychotics.
|
|---|---|
| ln Vitro |
(S)-Amisulpride (Esamisupride) binds to D2 and D3 receptors with great affinity. It works better than (R)-amisulpride and has about double the impact on these receptors as lacasulpride. 20–50 times [2]
In vitro, (S)-Amisulpride binds to dopamine D2 and D3 receptors with high affinity, displacing radiolabeled ligands from these receptors. It shows selectivity for D3 over D2 receptors. It has low affinity for D1, D4, and D5 receptors, and no significant affinity for serotonin, histamine, or muscarinic receptors. Detailed binding affinities (Ki values) are not extensively reported in the available literature. |
| ln Vivo |
In male C57BL/6 mice, subcutaneous stimulation with 10 mg/kg of (S)-amisulpride is fast available, dose-related, time-dependent (effective between 30 and 120 minutes), and stereoselective [1].
In vivo, (S)-Amisulpride is used clinically for the treatment of schizophrenia and other psychotic disorders. It has been shown to be effective in reducing both positive and negative symptoms of schizophrenia. The compound is administered orally and is well-absorbed. Its in vivo efficacy has been demonstrated in numerous clinical trials. Detailed in vivo data from animal models are not extensively reported. |
| Enzyme Assay |
Non-cell-based receptor binding assays for (S)-Amisulpride use membrane preparations from cells expressing human dopamine D2 and D3 receptors. The compound is incubated with a radiolabeled dopamine receptor ligand (e.g., [3H]-spiperone or [3H]-raclopride) at varying concentrations. Binding affinity (Ki) is determined by measuring displacement of the radiolabeled ligand. Selectivity for D2 and D3 over other receptors is assessed using panels of receptor-binding assays.
|
| Cell Assay |
Cellular assays for (S)-Amisulpride utilize cells expressing dopamine D2 or D3 receptors to assess functional antagonism. Cells are treated with the compound at various concentrations, followed by stimulation with a dopamine receptor agonist (e.g., quinpirole). Downstream signaling such as cAMP inhibition or GTPγS binding is measured. IC50 values for receptor antagonism are determined from dose-response curves.
|
| Animal Protocol |
In vivo animal models for (S)-Amisulpride include standard antipsychotic screening models such as amphetamine-induced hyperactivity, apomorphine-induced climbing, and conditioned avoidance response in rodents. The compound is administered orally or intraperitoneally at various doses. Antipsychotic efficacy is assessed by behavioral parameters. Catalepsy tests may be used to assess extrapyramidal side effect potential.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (S)-Amisulpride include CAS number 71675-92-8. The compound is a small molecule benzamide derivative. It is orally active and well-absorbed. It has a molecular weight of approximately 369.5 g/mol. Detailed PK parameters such as half-life and bioavailability are established from clinical use of amisulpride.
|
| Toxicity/Toxicokinetics |
(S)-Amisulpride has a favorable safety profile compared to typical antipsychotics, with a lower risk of extrapyramidal symptoms. Detailed toxicological data are available from clinical use. Common side effects include weight gain, sedation, and gastrointestinal disturbances. The compound is for research use only in the context of this request.
|
| References |
[1]. Timothy J Donahue, et al. (S)-amisulpride as a discriminative stimulus in C57BL/6 mice and its comparison to the stimulus effects of typical and atypical antipsychotics. Eur J Pharmacol. 2014 Jul 5;734:15-22.
[2]. Vincent Grattan, et al. Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7. ACS Omega. 2019 Aug 15;4(9):14151-14154. |
| Additional Infomation |
(S)-Amisulpride is the (S)-enantiomer of amisulpride. It has CAS number 71675-92-8. It is a selective antagonist of dopamine D2 and D3 receptors, with higher affinity for D3 receptors. It is used in the treatment of schizophrenia and other psychotic disorders. It has a favorable side effect profile compared to typical antipsychotics. It is for research use only.
|
| Molecular Formula |
C17H27N3O4S
|
|---|---|
| Molecular Weight |
369.47898
|
| Exact Mass |
369.172
|
| CAS # |
71675-92-8
|
| PubChem CID |
3055076
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
558.9±50.0 °C at 760 mmHg
|
| Flash Point |
291.8±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
25
|
| Complexity |
549
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCN1CCCC1CNC(C1C=C(S(CC)(=O)=O)C(N)=CC=1OC)=O
|
| InChi Key |
NTJOBXMMWNYJFB-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)/t12-/m0/s1
|
| Chemical Name |
4-amino-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-5-ethylsulfonyl-2-methoxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~270.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7065 mL | 13.5325 mL | 27.0651 mL | |
| 5 mM | 0.5413 mL | 2.7065 mL | 5.4130 mL | |
| 10 mM | 0.2707 mL | 1.3533 mL | 2.7065 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
